Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 2
2008 5
2009 7
2010 7
2011 2
2012 9
2013 7
2014 5
2015 5
2016 1
2017 2
2019 8
2020 3
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

63 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean zhang zhen lin (117 results)?
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. Kim RD, et al. Among authors: lin zz. Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575541 Free article. Clinical Trial.
Clinical trials in hepatocellular carcinoma: an update.
Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY, Cheng AL. Shen YC, et al. Among authors: lin zz. Liver Cancer. 2013 Aug;2(3-4):345-64. doi: 10.1159/000343850. Liver Cancer. 2013. PMID: 24400222 Free PMC article. Review.
Sunitinib-induced myxedema coma.
Chen SY, Kao PC, Lin ZZ, Chiang WC, Fang CC. Chen SY, et al. Among authors: lin zz. Am J Emerg Med. 2009 Mar;27(3):370.e1-370.e3. doi: 10.1016/j.ajem.2008.07.012. Am J Emerg Med. 2009. PMID: 19328392 No abstract available.
63 results